The stock of SCYNEXIS Inc (NASDAQ:SCYX) is a huge mover today! About 1.24M shares traded hands or 42.80% up from the average. SCYNEXIS Inc (NASDAQ:SCYX) has declined 2.99% since March 15, 2016 and is downtrending. It has underperformed by 8.48% the S&P500.
The move comes after 9 months positive chart setup for the $93.95 million company. It was reported on Oct, 18 by Barchart.com. We have $5.63 PT which if reached, will make NASDAQ:SCYX worth $38.52M more.
Analysts await SCYNEXIS Inc (NASDAQ:SCYX) to report earnings on November, 11.
SCYNEXIS Inc (NASDAQ:SCYX) Ratings Coverage
Out of 5 analysts covering Scynexis Inc (NASDAQ:SCYX), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Scynexis Inc has been the topic of 8 analyst reports since August 20, 2015 according to StockzIntelligence Inc. The stock of SCYNEXIS Inc (NASDAQ:SCYX) earned “Buy” rating by WBB Securities on Tuesday, August 9. The firm has “Buy” rating by Guggenheim given on Wednesday, August 17. As per Thursday, August 20, the company rating was maintained by Needham. WBB Securities upgraded SCYNEXIS Inc (NASDAQ:SCYX) on Friday, October 7 to “Strong Buy” rating. The stock of SCYNEXIS Inc (NASDAQ:SCYX) earned “Outperform” rating by RBC Capital Markets on Monday, November 16. The rating was initiated by WBB Securities with “Strong Buy” on Tuesday, December 29. The stock of SCYNEXIS Inc (NASDAQ:SCYX) earned “Buy” rating by Brean Capital on Monday, October 3. The rating was initiated by Brean Capital on Monday, March 28 with “Buy”.
According to Zacks Investment Research, “SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina.”
Insitutional Activity: The institutional sentiment increased to 1.82 in 2016 Q2. Its up 0.02, from 1.8 in 2016Q1. The ratio improved, as 4 funds sold all SCYNEXIS Inc shares owned while 7 reduced positions. 10 funds bought stakes while 10 increased positions. They now own 13.69 million shares or 61.88% more from 8.46 million shares in 2016Q1.
Principal Fincl Gp last reported 202,938 shares in the company. Jacobs Levy Equity Mngmt Inc owns 26,100 shares or 0% of their US portfolio. Moreover, Deerfield Management has 0.15% invested in SCYNEXIS Inc (NASDAQ:SCYX) for 1.77 million shares. Blackrock Fund owns 30,090 shares or 0% of their US portfolio. Blackrock Investment Management Ltd Com last reported 2,041 shares in the company. Private Advisor Gp Incorporated Ltd Llc accumulated 200,000 shares or 0.02% of the stock. Millennium Management Ltd Liability Corp holds 0% of its portfolio in SCYNEXIS Inc (NASDAQ:SCYX) for 36,700 shares. Tower Limited Liability (Trc) reported 796 shares or 0% of all its holdings. The Massachusetts-based Fmr has invested 0% in SCYNEXIS Inc (NASDAQ:SCYX). Geode Capital Mgmt, a Massachusetts-based fund reported 55,168 shares. Rock Springs Cap Management Ltd Partnership accumulated 635,000 shares or 0.1% of the stock. California Employees Retirement Sys accumulated 200,000 shares or 0% of the stock. Deutsche National Bank Ag last reported 137,649 shares in the company. Blackrock Institutional Tru Na accumulated 0% or 4,201 shares. Sphera Funds Mngmt Limited holds 128,500 shares or 0.07% of its portfolio.
Insider Transactions: Since May 19, 2016, the stock had 7 buys, and 0 insider sales for $276,683 net activity. HANHAM ANN bought $15,379 worth of SCYNEXIS Inc (NASDAQ:SCYX) on Wednesday, May 25. Machado Patrick bought 40,000 shares worth $117,600. Angulo Gonzalez David had bought 36,950 shares worth $82,159. Taglietti Marco had bought 246 shares worth $787.
More news for SCYNEXIS Inc (NASDAQ:SCYX) were recently published by: Globenewswire.com, which released: “SCYNEXIS, Inc. to Present at the Ladenburg Thalmann Healthcare Conference” on September 20, 2016. Globenewswire.com‘s article titled: “SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment …” and published on August 24, 2016 is yet another important article.
SCYX Company Profile
SCYNEXIS, Inc., incorporated on November 4, 1999, is a pharmaceutical company, which is engaged in the discovery, development and commercialization of anti-infectives to address unmet therapeutic needs. The Firm is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. It also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. Candida and Aspergillus species are the fungi responsible for all invasive fungal infections in the United States and Europe. The Firm has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.